VCM
BEAM icon

Versant Capital Management’s Beam Therapeutics BEAM Stock Holding History

Versant Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19K Sell
554
-8
-1% -$242 ﹤0.01% 1955
2026
Q1 		$13.4K Buy
562
+362
+181% +$10K ﹤0.01% 2010
2025
Q4 		$5.54K Hold
200
– – ﹤0.01% 2220
2025
Q3 		$4.85K Hold
200
– – ﹤0.01% 2217
2025
Q2 		$3.4K Sell
200
-497
-71% -$8.65K ﹤0.01% 2282
2025
Q1 		$13.6K Buy
697
+5
+0.7% +$131 ﹤0.01% 1558
2024
Q4 		$17.2K Buy
692
+195
+39% +$4.98K ﹤0.01% 1110
2024
Q3 		$12.2K Buy
497
+433
+677% +$11.2K ﹤0.01% 991
2024
Q2 		$1.5K Buy
+64
New +$1.57K ﹤0.01% 1581
2023
Q4 		– Sell
-7
Closed -$168 – 1925
2023
Q3 		$168 Sell
7
-98
-93% -$2.63K ﹤0.01% 1892
2023
Q2 		$3.35K Buy
+105
New +$3.41K ﹤0.01% 1177

Other funds holding BEAM

Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
CIM
Contravisory Investment Management Norwell, Massachusetts $566M AUM 42.93% 1-Year Est. Return
BFS
Beacon Financial Strategies Raleigh, North Carolina $201M AUM 19.14% 1-Year Est. Return
TWM
Thrive Wealth Management Audubon, Pennsylvania $787M AUM 23.6% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
RF
Robinswood Financial Kirkland, Washington $349M AUM 14.9% 1-Year Est. Return
AP
Aspect Partners Fairfax, Virginia $268M AUM 22.57% 1-Year Est. Return

Versant Capital Management's BEAM Position: Q2 2026 in Review

Versant Capital Management reduced its Beam Therapeutics (BEAM) stake by 1.4% in Q2 2026, selling an estimated $242 and leaving 554 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #1955.

Versant Capital Management first reported a position in BEAM in Q2 2023 and has held it in 11 quarters since. 14 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • Versant Capital Management held 554 shares of Beam Therapeutics worth $19K as of Q2 2026.
  • Versant Capital Management sold 8 Beam Therapeutics shares in Q2 2026, an estimated $242.
  • Beam Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #1955 holding.
  • Versant Capital Management first reported a position in Beam Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • 14 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.